CVM CEL SCI CORP
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 725363 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY12.9%
TTM EPS YoY81.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-252.5%
ROA-108.9%
ROIC (approx.)-364.5%
Asset turnover—
Leverage & solvency
Liabilities / assets48.7%
Debt / equity0.00x
Current ratio1.48x
Interest coverage-50.08x
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-28.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $3.65M | $3.77M | $3.68M | $3.70M | $3.74M | $4.01M | $4.43M | $4.48M |
| SG&A expense | $1.91M | $1.56M | $1.69M | $2.33M | $1.75M | $2.38M | $2.46M | $1.64M |
| Operating income | -$5.56M | -$5.33M | -$5.37M | -$6.03M | -$5.49M | -$6.39M | -$6.89M | -$6.12M |
| Interest expense | $111,000 | $117,000 | $88,000 | $129,000 | $172,000 | $178,000 | $170,000 | — |
| Net income | -$5.67M | -$5.47M | -$5.47M | -$6.10M | -$5.66M | -$6.57M | -$7.07M | -$6.77M |
| EBITDA | -$4.61M | -$4.37M | -$4.40M | -$6.90M | -$4.53M | -$5.42M | -$5.90M | -$6.96M |
| EPS (diluted) | -0.47 | -0.67 | -0.68 | — | -1.36 | -2.33 | -3.25 | — |
| Weighted avg. shares (diluted) | 12.12M | 8.14M | 8.02M | — | 4.15M | 2.82M | 2.18M | — |
| Banking | ||||||||
| Net interest income | -$110,240 | -$117,485 | -$87,789 | -$128,505 | -$172,050 | -$178,286 | -$170,103 | -$174,571 |
| Balance sheet | ||||||||
| Cash & equivalents | $6.53M | $1.89M | $6.28M | $10.95M | $1.79M | $1.92M | $4.61M | $4.74M |
| Inventory | — | — | — | — | — | — | — | $1.02M |
| Current assets | $7.50M | $2.89M | $7.03M | $11.60M | $2.62M | $3.02M | $5.86M | $6.06M |
| PP&E, net | $4.58M | $5.07M | $5.57M | $6.08M | $6.58M | $7.08M | $7.59M | $8.13M |
| Intangibles | $69,688 | $73,328 | $101,548 | $119,856 | $130,585 | $141,263 | $148,394 | $165,492 |
| Total assets | $21.36M | $17.71M | $22.89M | $28.16M | $20.34M | $21.81M | $25.70M | $26.99M |
| Current liabilities | $5.08M | $4.81M | $5.04M | $5.13M | $5.62M | $5.50M | $5.48M | $4.62M |
| Short-term debt | — | — | — | $2.27M | — | — | — | — |
| Long-term debt | — | — | — | $5.68M | — | — | — | — |
| Total debt | — | — | — | $7.96M | — | — | — | — |
| Total liabilities | $10.40M | $10.83M | $11.76M | $12.20M | $13.31M | $13.81M | $14.39M | $14.12M |
| Shareholders' equity | $10.96M | $6.87M | $11.14M | $15.96M | $7.02M | $8.00M | $11.31M | $12.87M |
| Net debt | — | — | — | -$3.00M | — | — | — | — |
| Shares outstanding | 17.59M | 8.49M | 8.42M | 8.02M | 5.32M | 84.35M | 74.08M | 2.13M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.03M | -$4.02M | -$4.02M | -$4.67M | -$3.94M | -$4.37M | -$4.14M | -$4.82M |
| Capital expenditure | $0 | $0 | $0 | $5,155 | $0 | $0 | $32,954 | $19,753 |
| Free cash flow | -$4.03M | -$4.02M | -$4.02M | -$4.68M | -$3.94M | -$4.37M | -$4.17M | -$4.84M |
| Investing cash flow | $0 | $0 | $0 | -$5,155 | $0 | $0 | -$32,954 | -$19,753 |
| Financing cash flow | $8.67M | -$364,461 | -$653,773 | $13.84M | $3.81M | $1.68M | $4.05M | $9.19M |
| Depreciation & amortization | $946,370 | $956,401 | $964,422 | -$868,303 | $959,009 | $970,102 | $995,192 | -$842,603 |
| Stock-based compensation | $454,094 | $451,381 | $443,275 | $440,506 | $73,441 | $685,669 | $711,381 | $725,611 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.